mifepristone

The case could affect not just abortion access, but oversight of the drug industry and the authority of federal agencies. The court hears arguments Tuesday.

The court's action sets up a collision between the Food and Drug Administration's 23-year study and supervision of mifepristone, and the circumstances under which it can be prescribed.